Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioMedica ( (GB:OXB) ) just unveiled an update.
Oxford Biomedica PLC announced that its issued share capital consists of 120,497,010 ordinary shares, with no shares held in treasury, as of October 31, 2025. This figure represents the total number of voting rights in the company and is significant for shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £667.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s stock score is primarily influenced by its mixed financial performance, with strong revenue growth overshadowed by profitability and liquidity challenges. The technical analysis shows positive momentum, but valuation concerns due to ongoing losses weigh on the score.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, OXB is a pioneer in viral vectors, collaborating with leading pharmaceutical and biotechnology companies to provide expertise in lentivirus, adeno-associated virus, adenovirus, and other viral vector types. The company offers comprehensive services from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise. Headquartered in Oxford, UK, OXB operates facilities in the UK, France, and the US.
YTD Price Performance: 56.43%
Average Trading Volume: 259,451
Technical Sentiment Signal: Buy
Current Market Cap: £789.8M
See more data about OXB stock on TipRanks’ Stock Analysis page.